Clinical Features Associated with Bacteremia Due to Heterogeneous Vancomycin‐IntermediateStaphylococcus aureus
Clinical Infectious Diseases2004Vol. 38(3), pp. 448–451
Citations Over TimeTop 1% of 2004 papers
Abstract
We assessed all episodes of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia at our hospital during a 12-month period (n=53) and compared those due to heterogeneous vancomycin-intermediate S. aureus (hVISA; n = 5, 9.4%) with those due to vancomycin-susceptible MRSA (n=48). Patients with hVISA bacteremia were more likely to have high bacterial load infections (P=.001), vancomycin treatment failure (persistent fever and bacteremia for >7 days after the start of therapy; P<.001), and initially low serum vancomycin levels (P=.006). These clinical markers of hVISA bacteremia may help focus diagnostic efforts and treatment.
Related Papers
- → First Report of Vancomycin-Resistant Staphylococci Isolated from Healthy Carriers in Brazil(2005)106 cited
- → Predictors of Relapse of Methicillin-Resistant Staphylococcus aureus Bacteremia after Treatment with Vancomycin(2011)40 cited
- → Evidence for a Continuum of Decreased Vancomycin Susceptibility in UnselectedStaphylococcus aureusClinical Isolates(2002)49 cited
- → Clinical Characteristics and Outcomes of Persistent Staphylococcal Bacteremia in a Tertiary Care Hospital(2023)5 cited
- → Treatment of chronic experimentalStaphylococcus aureus osteomyelitis with LY146032 and vancomycin(1989)23 cited